Andrea Zivi
Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations
Schmid S, De Giorgi U, Hansen A, Beer T, Lavaud P, Morales-Barrera R, Tucci M, Castro E, Karalis K, Bergman A, Le M, Zürrer-Härdi U, Pezaro C, Suzuki H, Zivi A, Klingbiel D, Schär S, Bianchini D, Chi K, Omlin A, Higano C, Sweeney C, Martinez Chanza N, Mehra N, Kuppen M, Beltran H, Conteduca V, Vargas Pivato de Almeida D, Cotait Maluf F, Oh W, Tsao C, Sartor O, Ledet E, Di Lorenzo G, Yip S, Gillessen S. Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations. JAMA Netw Open 2020; 3:e2021692.
Oct 1, 2020Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations
Oct 1, 2020JAMA Netw Open 2020; 3:e2021692
Schmid Sabine, De Giorgi Ugo, Hansen Aaron R, Beer Tomasz M, Lavaud Pernelle, Morales-Barrera Rafael, Tucci Marcello, Castro Elena, Karalis Kostas, Bergman Andries M, Le Mo Linh, Zürrer-Härdi Ursina, Pezaro Carmel, Suzuki Hiroyoshi, Zivi Andrea, Klingbiel Dirk, Schär Sämi, Bianchini Diletta, Chi Kim N, Omlin Aurelius, Higano Celestia, Sweeney Christopher, Martinez Chanza Nieves, Mehra Niven, Kuppen Malou C P, Beltran Himisha, Conteduca Vincenza, Vargas Pivato de Almeida Daniel, Cotait Maluf Fernando, Oh William K, Tsao Che-Kai, Sartor Oliver, Ledet Elisa, Di Lorenzo Giuseppe, Yip Steven M, Gillessen Silke
Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative Analysis
Rescigno P, Romero-Laorden N, Castro E, Saez M, Mehra N, Smeenk S, Sideris S, Gil T, Banks P, Sandhu S, Sternberg C, De Giorgi U, Olmos D, Morley C, Pezaro C, Dolling D, Conteduca V, Rediti M, Bianchini D, Lolli C, Ong M, Li H, Omlin A, Schmid S, Caffo O, Zivi A, de Bono J. Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative Analysis. Eur Urol Oncol 2019
Jul 12, 2019Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative Analysis
Jul 12, 2019Eur Urol Oncol 2019
Rescigno Pasquale, Romero-Laorden Nuria, Castro Elena, Saez Maria I, Mehra Niven, Smeenk Stella, Sideris Spyridon, Gil Thyerry, Banks Patricia, Sandhu Shaneen K, Sternberg Cora N, De Giorgi Ugo, Olmos David, Morley Courtney, Pezaro Carmel J, Dolling David, Conteduca Vincenza, Rediti Mattia, Bianchini Diletta, Lolli Cristian, Ong Michael, Li Haoran, Omlin Aurelius, Schmid Sabine, Caffo Orazio, Zivi Andrea, de Bono Johann S
Volume of Bone Metastasis Assessed with Whole-Body Diffusion-weighted Imaging Is Associated with Overall Survival in Metastatic Castration-resistant Prostate Cancer
Pérez-López R, Koh D, de Bono J, Leach M, Zivi A, Omlin A, Bianchini D, Mateo J, Collins D, Blackledge M, Lorente D, Tunariu N. Volume of Bone Metastasis Assessed with Whole-Body Diffusion-weighted Imaging Is Associated with Overall Survival in Metastatic Castration-resistant Prostate Cancer. Radiology 2016; 280:151-60.
Jan 25, 2016Volume of Bone Metastasis Assessed with Whole-Body Diffusion-weighted Imaging Is Associated with Overall Survival in Metastatic Castration-resistant Prostate Cancer
Jan 25, 2016Radiology 2016; 280:151-60
Pérez-López Raquel, Koh Dow-Mu, de Bono Johann S, Leach Martin O, Zivi Andrea, Omlin Aurelius, Bianchini Diletta, Mateo Joaquin, Collins David J, Blackledge Matthew D, Lorente David, Tunariu Nina
First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokinetics, and pharmacodynamics, in patients with metastatic cancer
Blagden S, Spicer J, Twelves C, Jones K, Prince J, Inatani M, Shiokawa R, Noguchi K, Pope L, Riisnaes R, Swales K, Decordova S, Anthoney A, Pinato D, Zivi A, Stavraka C, Josephs D, Omlin A, Banerji U. First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokinetics, and pharmacodynamics, in patients with metastatic cancer. Clin Cancer Res 2014; 20:5908-17.
Sep 17, 2014First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokinetics, and pharmacodynamics, in patients with metastatic cancer
Sep 17, 2014Clin Cancer Res 2014; 20:5908-17
Blagden Sarah, Spicer James, Twelves Chris, Jones Keith, Prince Jenny, Inatani Michiyasu, Shiokawa Rie, Noguchi Kohei, Pope Lorna, Riisnaes Ruth, Swales Karen, Decordova Shaun, Anthoney Alan, Pinato David J, Zivi Andrea, Stavraka Chara, Josephs Debra, Omlin Aurelius, Banerji Udai
Reply to: Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate resistant prostate cancer
Lorente D, Chowdhury S, Attard G, Zivi A, Ferraldeschi R, Pezaro C, Omlin A, Rodriguez-Vida A, Bianchini D, de Bono J. Reply to: Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate resistant prostate cancer. Eur J Cancer 2014; 50:1042-3.
Jan 13, 2014Reply to: Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate resistant prostate cancer
Jan 13, 2014Eur J Cancer 2014; 50:1042-3
Lorente David, Chowdhury Simon, Attard Gerhardt, Zivi Andrea, Ferraldeschi Roberta, Pezaro Carmel, Omlin Aurelius, Rodriguez-Vida Alejo, Bianchini Diletta, de Bono Johann S
The changing therapeutic landscape of castration-resistant prostate cancer
Yap T, Zivi A, Omlin A, de Bono J. The changing therapeutic landscape of castration-resistant prostate cancer. Nat Rev Clin Oncol 2011; 8:597-610.
Aug 9, 2011The changing therapeutic landscape of castration-resistant prostate cancer
Aug 9, 2011Nat Rev Clin Oncol 2011; 8:597-610
Yap Timothy A, Zivi Andrea, Omlin Aurelius, de Bono Johann S